Lazap

Olanzapine, the active ingredient in Lazap, is an atypical antipsychotic presented as an oral tablet for oral use. It is prescribed for the management of schizophrenia and bipolar disorder in adult patients. GNH USA supplies Lazap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine acts on central neurotransmitter pathways to treat serious mental health conditions. - Schizophrenia: alleviates psychotic symptoms such as delusions, hallucinations and thought disorder. - Bipolar disorder: stabilises mood and reduces the frequency of manic and depressive episodes.

Olanzapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Weight gain: increased appetite leading to noticeable weight increase. - Sedation: drowsiness or feeling unusually tired. - Dry mouth: reduced salivation causing oral discomfort. - Constipation: slowed gastrointestinal motility. - Dizziness: light‑headedness, especially when standing quickly. - Increased appetite: heightened desire for food.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe reduction in white blood cells. - Hyperglycemia: marked elevation of blood sugar levels. - Seizures: occurrence of convulsive episodes. - Tardive dyskinesia: involuntary, repetitive movements. - Myocarditis: inflammation of the heart muscle.

When prescribing or dispensing Olanzapine, consider the following safety measures. - Monitor metabolic parameters: regularly assess weight, glucose and lipid levels. - Assess for cardiovascular risk: evaluate blood pressure and lipid profile before initiation. - Evaluate hepatic function: adjust use in patients with liver impairment. - Review psychiatric history: be cautious in patients with a history of suicidal ideation. - Avoid abrupt discontinuation: taper dose under medical supervision to prevent relapse. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Olanzapine can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine): may raise olanzapine plasma concentrations. - CNS depressants (e.g., benzodiazepines): additive sedation and respiratory depression. - Anticholinergic agents: increased anticholinergic burden leading to confusion.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., smoking, carbamazepine): may lower olanzapine levels. - Antihypertensives: potential enhancement of hypotensive effect. - Lithium: may increase risk of neurotoxicity when combined.